• 1. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 2. An integrated system for field analysis of Cd(ii) and Pb(ii) via preconcentration using nano-TiO2/cellulose paper composite and subsequent detection with a portable X-ray fluorescence spectrometer?
  Xiaofeng Lin RSC Adv., 2016,6, 9002-9006
• 3. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 4. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 5. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550

Comprehensive Analysis of 2-Bromo-N-(4-fluorophenyl)propanamide (CAS No. 905797-71-9): Properties, Applications, and Industry Insights

2-Bromo-N-(4-fluorophenyl)propanamide (CAS No. 905797-71-9) is a specialized organic compound gaining traction in pharmaceutical and agrochemical research due to its unique molecular structure. This bromo-substituted amide derivative features a fluorophenyl group, making it a valuable intermediate for synthesizing bioactive molecules. Recent studies highlight its potential in kinase inhibitor development, aligning with the growing demand for targeted therapies in oncology and inflammation treatment.

The compound's structure-activity relationship (SAR) has attracted attention in drug discovery circles, particularly for its hydrogen bonding capabilities and electrophilic reactivity. Researchers are investigating its role in creating covalent inhibitors, a hot topic in precision medicine development. With molecular weight of 246.08 g/mol and purity standards exceeding 98%, 905797-71-9 meets stringent requirements for high-throughput screening applications.

From a synthetic chemistry perspective, 2-Bromo-N-(4-fluorophenyl)propanamide demonstrates remarkable regioselectivity in nucleophilic substitution reactions. Its 4-fluorophenyl moiety enhances compound stability while the bromopropanamide group serves as an excellent leaving group. These properties make it ideal for constructing heterocyclic scaffolds, addressing the pharmaceutical industry's need for diverse chemical space exploration.

Environmental considerations surrounding halogenated compounds have led to innovations in green chemistry applications of this material. Advanced catalytic processes now enable efficient synthesis with reduced waste generation, responding to sustainability concerns in chemical manufacturing. The compound's biodegradation profile is currently under study as part of broader eco-friendly chemistry initiatives.

Analytical characterization of CAS 905797-71-9 typically involves HPLC-MS and NMR spectroscopy, with particular focus on its 1H-NMR spectrum showing characteristic signals at δ 7.6-7.8 ppm (aromatic protons) and δ 4.3 ppm (CH₂-Br). These spectroscopic fingerprints are crucial for quality control in contract research organizations (CROs) and API manufacturing facilities.

Market trends indicate rising demand for fluorinated building blocks like 2-Bromo-N-(4-fluorophenyl)propanamide, driven by expanding orphan drug development and personalized medicine initiatives. The compound's lipophilicity (calculated logP ≈ 2.1) makes it particularly valuable for CNS drug discovery programs seeking to optimize blood-brain barrier penetration.

Recent patent literature reveals innovative applications of this bromoamide derivative in proteolysis targeting chimera (PROTAC) technology, a cutting-edge approach in targeted protein degradation. Its ability to serve as a linker component between E3 ligase binders and target proteins has opened new avenues in undruggable target research.

Handling and storage recommendations for 905797-71-9 emphasize protection from moisture-sensitive conditions and storage at 2-8°C under inert atmosphere. These protocols ensure stability of the reactive bromine center while maintaining the compound's synthetic utility over extended periods.

Emerging computational chemistry approaches are being applied to predict novel derivatives of 2-Bromo-N-(4-fluorophenyl)propanamide, leveraging AI-assisted drug design platforms. This aligns with industry shifts toward in silico screening methods to accelerate hit-to-lead optimization cycles in drug development pipelines.

The global market for fluorophenyl-containing intermediates is projected to grow at 6.8% CAGR through 2030, with CAS 905797-71-9 positioned as a key player in this segment. Manufacturers are investing in continuous flow chemistry systems to enhance production scalability while maintaining the compound's critical chiral purity standards.

Academic and industrial researchers frequently inquire about the cross-coupling reactivity of 2-Bromo-N-(4-fluorophenyl)propanamide, particularly in Buchwald-Hartwig amination and Suzuki-Miyaura reactions. The compound's performance in these palladium-catalyzed transformations makes it valuable for constructing complex pharmacophores in medicinal chemistry programs.

Quality specifications for pharmaceutical-grade 905797-71-9 typically require ≤0.5% of any single impurity by HPLC analysis, with special attention to genotoxic impurity control. These standards reflect evolving ICH guidelines and quality by design (QbD) principles in modern active pharmaceutical ingredient (API) development.

Recent breakthroughs in bioconjugation chemistry have identified 2-Bromo-N-(4-fluorophenyl)propanamide as a potential protein labeling reagent, particularly for cysteine-targeting applications. This expands its utility beyond small molecule synthesis into biologics engineering and antibody-drug conjugate (ADC) development.

The compound's crystallographic data reveals important packing interactions between the fluorophenyl ring and amide carbonyl, information valuable for polymorph screening in formulation development. Such structural insights guide the design of co-crystals to improve drug solubility and bioavailability.

Looking ahead, 2-Bromo-N-(4-fluorophenyl)propanamide is poised to play a significant role in addressing current challenges in drug resistance and multi-target therapeutics. Its versatile chemistry supports the creation of hybrid molecules that may combat complex diseases through polypharmacology mechanisms, representing an exciting frontier in next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)